Cost-effectiveness of intravenous proton pump inhibitors in high-risk bleeders.
van Zanten
Sander Veldhuyzen
SV
Dalhousie Medical School, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. zanten@dal.ca
D000284:Administration, Oral; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000191:economics / Q000209:etiology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000191:economics*; D005744:Gastric Acid / Q000378:metabolism; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy / Q000191:economics / Q000209:etiology; D054328:Proton Pump Inhibitors; D012008:Recurrence; D012307:Risk Factors; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy / Q000191:economics
D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors